Brief: Candel says CAN-3110 Receives FDA Fast Track Designation for Treatment of Recurrent High-Grade Glioma

Candel Therapeutics

13/02/2024 13:09

Feb 13 (Reuters) - Candel Therapeutics Inc  CADL.O :
    * CAN-3110 RECEIVES FDA FAST TRACK DESIGNATION FOR TREATMENT
OF
RECURRENT HIGH-GRADE GLIOMA
    * CAN-3110 RECEIVES FDA FAST TRACK DESIGNATION FOR TREATMENT
OF
RECURRENT HIGH-GRADE GLIOMA
    * CANDEL THERAPEUTICS INC: TO REPORT ADDITIONAL DATA FOR
CAN-3110,
FROM ONGOING PHASE 1B CLINICAL TRIAL IN SECOND HALF 2024

Source text for Eikon:  ID:nGNX4ZXCfK 
Further company coverage:  CADL.O 

 ((Reuters.Briefs@thomsonreuters.com;))